Overview

• Medical device maker's 2025 sales grew 19.5%, driven by 23.2% rise in medical sales

• Q4 sales slightly missed analyst expectations

• Company faced $6.3 mln labor inefficiencies at AJR facility, expects continued progress

Outlook

• Company plans to add a new facility in Dominican Republic in Q2 2026

• UFP Technologies expects significant growth in Safe Patient Handling market in 2026

• Company remains bullish about future due to new talent and contract extensions

Result Drivers

• MEDICAL SALES GROWTH - Co's 2025 revenue growth was driven by a 23.2% increase in medical sales

• LABOR INEFFICIENCIES - Co absorbed $6.3 mln in labor-related inefficiencies at AJR facility, impacting FY earnings

Company press release: ID:nGNX2tGqQV

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Sales	Slight Miss*	$148.92 mln	$149.07 mln (4 Analysts)
Q4 EPS		$2.28
Q4 Net Income		$17.57 mln
Q4 Gross Profit		$41.97 mln
Q4 Operating Income		$21.50 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for UFP Technologies Inc is $329.50, about 36.3% above its February 23 closing price of $241.79

• The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.